We have recently paired with Arxx Therapeutics to help deliver their clinical trial. With the help of MEU and CRO Solutions, Arxx is happy to share that they have completed dosing of all healthy volunteers in their ongoing phase 1 study and successfully initiated the multiple ascending dose part in patients with psoriasis.

Professor Dave Singh, MEU Medical Director and Professor of Clinical Pharmacology and Respiratory Medicine, University of Manchester, presented at the European Respiratory Society (ERS) International Congress, Milan, earlier this week.

The ERS is an annual event that brings together the world’s respiratory experts to showcase the latest advances in respiratory medicine and science.

Professor Singh presented subjects including “Inhaled Corticosteroids in COPD: Who and When?” and “The Evolving Landscape in COPD and Implications for Disease Management”.

MEU Chairman and Professor of Respiratory Medicine, Ashley Woodcock, was interviewed on BBC Radio 4’s Today Show this morning about some good news concerning the environment.

Professor Woodcock spoke to Nick Robinson about how the ozone layer is on course to being repaired thanks to a decision to phase out CFCs (gases found in products such as aerosols, fridges and foam insulation) through the Montreal Protocol.

Professor Dave Singh, Medical Director of The Medicines Evaluation Unit (MEU), was interviewed by La Nación, a leading Argentine daily news publication about today’s challenges in asthma management.

Mi-Trial, a new company which has developed an innovative clinical trial companion system and app, has recently spun out from the University of Manchester with support from Elaros 24/7 Limited, Medicines Evaluation Unit Limited and the University of Manchester Innovation Factory.

A study which tested the immune response of COPD patients to COVID-19 vaccination has shown they respond in a similar way to healthy people.

On Sunday May 8th MEU took part in the Manchester Charity Dragon Boat Challenge at Sale Water Park. MEU successfully raised over £500 for Manchester Young Lives.

EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.

We’re delighted to support our local volunteer blood bike service, Blood Bikes Manchester with our recent donation of £2,000. We believe that this is an invaluable resource to society and we aim to help the charity where we can. To date, we have raised £7,000 for this worthy cause!

Our Directors of Operations, David Rogers, was one of a few guests selected to personally meet HRH The Prince of Wales at a reception held for the 2020 and 2021 winners of the Queen’s Award for Enterprise at Windsor Castle on Wednesday, 10th November.